Mary Kay Inc. & European Society for Dermatological Research Partner to Award Educational Research Grants Advancing Skin Health/Skin Disease
17.5.2023 19:05:00 EEST | Business Wire | Press release
Mary Kay Inc., a global leader in skin care innovation, in partnership with the European Society for Dermatological Research, recently announced its inaugural Mary Kay Skin Health/Skin Disease Research Grant awardees at a special virtual event prior to the First International Societies for Investigative Dermatology conference in May. Grant recipients are researchers conducting groundbreaking, innovative studies in skin health and skin disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005040/en/
Mary Kay partnered with European Society for Dermatological Research (ESDR) to award inaugural Mary Kay-ESDR Skin Health/Skin Disease Research Grants. Congratulations to our 2022 recipients, Dr. Clarisse Ganier and Dr. Michael Cangkrama, who will each receive $20,000 grants to further their contributions in skin disease research. (Photo: Mary Kay Inc.)
“Mary Kay is dedicated to advancing skin and nutritional health research globally, and we know this cannot be done alone. Collaboration across industries, academic institutions, and clinicians is critical, which is why we are proud to partner with ESDR to furnish the first-ever Mary Kay-ESDR Skin Health/Skin Disease Research Grants,” said Dr. Lucy Gildea, Chief Innovation Officer, Product and Science at Mary Kay. “These grants bring this larger community together for new inspiration for the future, and Mary Kay is proud to be a part of this opportunity. We are excited to see how these recipients bring greater advancements to different aspects of skin health research.”
The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with ESDR. The $20,000 grants were to be awarded to two researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2022 ESDR meeting, the company received applications from scientists across all of Europe.
The two grant awardees ultimately selected were:
- Dr. Michael Cangkrama, (Switzerland) Senior Scientist, Department of Biology, Institute of Molecular Health Sciences, ETH Zürich – Dr. Cangkrama is working on molecular and cellular mechanisms underlying the development and progression of epithelial skin cancers, the most common types of cancer in humans. His research projects will focus on investigating molecular mechanisms of squamous cancer development and the role of the tumor microenvironment using state-of-the-art approaches. He will utilize the grant to further develop his independent projects and continue to pursue positions as an independent group leader or Assistant Professor in Europe.
- Dr. Clarisse Ganier, (United Kingdom), Research Associate at the Center of Gene Therapy and Regenerative Medicine in King’s College London. Dr. Ganier is part of the Human Cell Atlas initiative – an international collaborative effort to map all cell types within the human body – to generate a comprehensive Skin Cell Atlas. As part of this work, they have created a multi-scale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating single cell transcriptomics, in vivo optical coherence tomography, spatial global transcriptional profiling and in situ sequencing. Funding for this research will allow her to pursue her professional goals of starting her own laboratory focusing on skin cancer biology by combining multiomics data, both in vitro and ex vivo.
“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the European Society for Dermatological Research—and we are thrilled to support their research.”
“On behalf of the ESDR board, we would like to thank Mary Kay for its support of the ESDR and congratulate this year’s grant recipients for their tremendous contributions to their respective fields. A key objective of our Society is to promote innovative research in investigative dermatology and to support researchers' activities in translational skin research,” said Eli Sprecher, Chair, Scientific Program Committee of ESDR.
The sponsorship and grants, revealed leading up to the inaugural International Societies for Investigative Dermatology Conference in Tokyo, are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies and packaging designs in its global portfolio.
View the full Mary Kay-ESDR Skin Health/Skin Disease Research Grants Ceremony recording here.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in more than 35 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook , Instagram, and LinkedIn or follow us on Twitter.
About European Society for Dermatological Research (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and toward improving the health of patients suffering from skin and venereal diseases. The ESDR facilitates the exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005040/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom